Navigation Links
PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Date:11/8/2012

INCLINE VILLAGE, Nev., Nov. 8, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 4:30 p.m. ET in New York City.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)  

This presentation will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the event to allow for any software download that may be necessary. The archived webcast will be available for seven days following the presentation.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.  


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
2. John A. Orwin Joins Array BioPharma Board Of Directors
3. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
5. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
6. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
7. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
8. PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
9. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
10. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
11. PDL BioPharma Announces Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ... and clinical data from its phase 1/2 tendon repair study ... fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The clinical ... at 6 months and showed no serious adverse events related ...
(Date:3/28/2017)... ... ... Executive search firm, Slone Partners, announces the placement of ... distinguished life sciences expert with a proven track record in strategic global business ... of services related to laboratory testing and analysis for the pharmaceutical, medical device, ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), a ... disease and more through a single-cell precision engineering platform, today announced it has ... in the laboratory of Dr. James Heath at the California Institute of ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small cell ... with limited tumor content in a large background of normal or wild type ... need for reliable detection of low abundance somatic mutations, particularly in small specimens ...
Breaking Biology Technology:
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):